Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17919158 | 1.00 | FAAH (0.44) | FAAHHDAC1BCHECNR2L3MBTL1 | |
| SCHEMBL21479482 | 0.89 | CA1 (0.40) | FAAHHDAC1BCHECNR2CA12 | |
| SCHEMBL21479563 | 0.88 | ABCG2 (0.40) | FAAHHDAC1BCHECNR2L3MBTL1 | |
| SCHEMBL17919107 | 0.86 | CA1 (0.50) | BCHECNR2CA12CA1CA2 | |
| SCHEMBL27445962 | 0.85 | KDM4E (0.41) | ABCG2GAAABCB1 | |
| SCHEMBL15849827 | 0.84 | HDAC8 (0.45) | FAAHABCG2 | |
| SCHEMBL13764449 | 0.84 | HDAC8 (0.45) | FAAHABCG2 | |
| SCHEMBL13820229 | 0.84 | HDAC8 (0.45) | FAAHABCG2 | |
| SCHEMBL21100866 | 0.83 | HDAC1 (0.48) | FAAHHDAC1BCHECNR2L3MBTL1 | |
| SCHEMBL30670755 | 0.83 | L3MBTL1 (0.51) | FAAHHDAC1BCHECNR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773540-B1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2019199532-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC (US) | 2019-10-17 | — | — | WO | disclosed |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | FAAH 3079/4885HDAC1 2731/4885BCHE 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.